Navigation Links
Prognosis of tumors positive for human papilloma virus in head and neck cancers varies according to the site
Date:4/5/2014

ncers we found no prognostic impact of being HPV positive in any of these endpoints," Dr Lassen will say. "This indicates that HPV status does not help us in predicting response to treatment, and hence the outcome of these cancers.

"We know from laboratory studies that HPV positive tumour cells are much more sensitive to radiation therapy than HPV negative cells, so until now we believed that they would behave similarly irrespective of site," Dr Lassen will say. "However, these data indicate that this is not the case, and at present we do not understand why this should be, though it probably can be ascribed to other biological/genetic differences between the tumours rather than the HPV status. We would now like to try to elucidate the underlying mechanisms behind these different outcomes."

There could be, for example, biological and/or genetic differences between the tumours other than the HPV status, the researchers say; for example, genetic changes caused by smoking tobacco, differences due to tumours of mixed make-up (for example, a combination of HPV+ and tobacco), or perhaps simply differences due to the site. "Such tumours with a combination of causes represent a challenge in our clinical daily practice," Dr Lassen will say.

"We have started following up our work by analysing all the tumour samples using polymerase chain reaction, a way of amplifying DNA in order to be able to analyse changes in genetic information. We hope this will enable us to understand more about why the role of HPV in non-oropharyngeal tumours is so different. There are few data available on this subject at present, so finding out will be an important step towards optimising treatment for these patients."

President of ESTRO, Professor Vincenzo Valentini, a radiation oncologist at the Policlinico Universitario A. Gemelli, Rome, Italy, commented: "These findings will have an important impact on the treatment of HPV+ head and neck cancers, and are likel
'/>"/>

Contact: Mary Rice
mary.rice@riceconseil.eu
European Society for Radiotherapy and Oncology (ESTRO)
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Repeated hUCB injections may improve prognosis of children with deadly inherited disorder
2. Classification system for bladder cancer prognosis
3. Certain symptom clusters experienced after surgery for esophageal cancer predict poor prognosis
4. Cancer/Tumor Profiling Market (Personalized Medicine, Biomarker Discovery, Prognosis, Research) Worth $35.03 Billion by 2018 – New Report by MarketsandMarkets
5. In prostate cancer prognosis, telomere length may matter
6. PET/CT bests gold standard bone marrow biopsy for diagnosis and prognosis of lymphoma patients
7. Examination of lymph nodes provides more accurate breast cancer prognosis
8. Accurate prognosis for epilepsy patients
9. DREAM and Sage Bionetworks tap the wisdom of the crowd to impact breast cancer prognosis
10. Smoking linked with worse urothelial cancer prognosis in patients, especially women
11. Routine blood test predicts prognosis in aggressive skin cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the ... for 2014. The awards program, created in 2000, is ... in the country. The program is a public/private partnership ... and Economic Development, the Pennsylvania State Council of the ... Business Journal. , Charlie Wilson, Vice President ...
(Date:12/25/2014)... 26, 2014 The click ... beauty, strength and durability. Today, the business announces ... is valid until Jan. 30, 2015. , Click ... traditional hardwood. BambooFlooringChina.com is a well-known brand in ... worldwide to find a reliable bamboo flooring supplier. ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Helen ... home in Woodland Hills, California after an 8 year ... away on Christmas Eve evening in her home in ... aggressive metastatic breast cancer. , As ... over forty years, she pioneered and championed many of ...
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- Overeating is common during ... eat in moderation, an expert says. "Don,t arrive at ... calories if you know you,ll be attending a party, but ... Ashbey-Pejoves, lead dietitian at Northern Westchester Hospital in Mount Kisco, ... to eat healthy during the day and even to have ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... , ( ) , , , ... N.J., Aug. 6 Smart Balance, Inc. (Nasdaq: SMBL ) today announced its ... of $58.2 million, an increase of 21.2% versus year ago, and earnings per share of ... The second quarter net sales increase versus 2008 was due to a 13% ...
... Lifestyle changes up the odds for Cubans, Puerto Ricans, Mexicans, ... Hispanics who move to the United States, the good life ... their risk for cancer by 40 percent. , Living the ... University of Miami Miller School of Medicine. , Of three ...
... , NASHVILLE, Tenn. and GLEN ... find that 76 percent of surveyed pharmacy directors say ... will have only one preferred biologic for all immune ... ulcerative colitis. According to the new Formulary Forum report ...
... , , REDWOOD CITY, ... ) today announced that Kim Popovits, Genomic Health,s Chief Executive Officer, ... in Boston, on Thursday, August 13 at 1:30 p.m. ET. , ... webcast of the presentation, visit the Investor Relations section of Genomic ...
... , , HOUSTON, ... first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a ... cancer. The disease-specific trial is being conducted under a Bellicum Investigational ... anticipates reporting initial results of the study in 2010. , ...
... KIBBUTZ SHAMIR, Israel, Aug. 6 Shamir Optical ... issue its second quarter of 2009 earnings results on Thursday, August 13(th), ... 11:00 A.M. EDT that morning. , , The ... live, please go to www.kcsa.com approximately five minutes ...
Cached Medicine News:Health News:Smart Balance Announces 2009 Second Quarter Results 2Health News:Smart Balance Announces 2009 Second Quarter Results 3Health News:Smart Balance Announces 2009 Second Quarter Results 4Health News:Smart Balance Announces 2009 Second Quarter Results 5Health News:Smart Balance Announces 2009 Second Quarter Results 6Health News:Smart Balance Announces 2009 Second Quarter Results 7Health News:Smart Balance Announces 2009 Second Quarter Results 8Health News:Smart Balance Announces 2009 Second Quarter Results 9Health News:Smart Balance Announces 2009 Second Quarter Results 10Health News:Living in U.S. May Raise Hispanics' Cancer Risk 2Health News:Living in U.S. May Raise Hispanics' Cancer Risk 3Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 2Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 3Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 2Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results 2
(Date:12/24/2014)... , Dec. 24, 2014  Commonwealth Cornerstone Group (CCG) ... Tax Credits transaction on Tuesday to help fund the expansion ... (PHN) in Sharon . ... Pennsylvania . It is the largest employer ... more than 150 people on staff. Currently, PHN ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
(Date:12/24/2014)... BEIJING , Dec. 24, 2014  The International Trade ... by ResMed (RMD) against BMC Medical. In a notice issued ... and found that ResMed,s patent on its humidifier was invalid. ... decision a "monumental win". "We are very excited with the ... the position that we have taken since the very beginning ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... 10 A recent national survey of 505 pharmacists found ... for a patient to seek treatment early to help shorten ... percent of pharmacists say most patients should purchase over-the-counter (OTC) ... while only 26 percent of their patients take this proactive ...
... Nov. 10 Reportlinker.com announces that a ... its catalogue. , Injectable Drug ... , http://www.reportlinker.com/p0158352/Injectable-Drug-Delivery-Market-Impact-and-Industry-Trends.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... grows, companies are increasingly looking towards the ...
Cached Medicine Technology:Pharmacists Report Patients do not Treat Cold and Flu Symptoms Early Enough, New Survey Shows 2Pharmacists Report Patients do not Treat Cold and Flu Symptoms Early Enough, New Survey Shows 3Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 2Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 3Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 4Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 5Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 6
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... Vitros 250 is a flexible ... in multiple environments small ... clinics and satellite locations. The ... dilution, and can be automated ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
Medicine Products: